NMDA or AMPA/kainate receptor blockade prevents acquisition of conditioned place preference induced by D(2/3) dopamine receptor stimulation in rats - PubMed (original) (raw)

. 2005 Apr;179(1):189-97.

doi: 10.1007/s00213-005-2201-y. Epub 2005 Mar 3.

Affiliations

NMDA or AMPA/kainate receptor blockade prevents acquisition of conditioned place preference induced by D(2/3) dopamine receptor stimulation in rats

Anna-Maria Biondo et al. Psychopharmacology (Berl). 2005 Apr.

Abstract

Rationale: Recent experiments from this laboratory demonstrated synergistic effects of AMPA/kainate receptor blockade and D(2/3) dopamine (DA) receptor stimulation on brain stimulation reward and locomotor activity.

Objectives: Using place conditioning, this study explored further the interaction between DA and glutamate (Glu) using the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801, the AMPA/kainate receptor antagonist NBQX, and the D(2/3) DA receptor agonist 7-OH-DPAT.

Methods: Effects of these compounds, alone and combined, were measured in male Sprague--Dawley rats using an unbiased two-compartment place conditioning procedure.

Results: 7-OH-DPAT (0.03--5.0 mg kg(-1), s.c.) administered immediately prior to conditioning was ineffective; when administered 15 min prior to conditioning, only the highest dose (5.0 mg kg(-1), s.c.) induced conditioned place preference (CPP). Acquisition of 7-OH-DPAT-induced CPP was blocked by MK-801 (0.06 or 0.13 mg kg(-1), i.p.) or NBQX (0.5 microg) microinjected into the nucleus accumbens (NAS) shell subregion. Intra-NAS shell administration of 7-OH-DPAT (5.0 microg) or NBQX (0.5 microg), alone or combined, failed to induce place conditioning, and this lack of effect was not due to state dependency. Administration of MK-801 or 7-OH-DPAT (5.0 mg kg(-1)) during the conditioning phase acutely increased horizontal activity, but neither compound, alone or combined, induced conditioned locomotor effects.

Conclusions: Acquisition of place conditioning induced by systemic administration of 7-OH-DPAT is blocked by systemic NMDA receptor antagonism by MK-801 or by the AMPA/kainate receptor antagonist NBQX microinjected into the NAS shell subregion.

PubMed Disclaimer

References

    1. J Neural Transm Gen Sect. 1994;95(1):71-4 - PubMed
    1. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(2-3):315-22 - PubMed
    1. Brain Res. 1995 Oct 30;697 (1-2):76-82 - PubMed
    1. Behav Pharmacol. 1998 Sep;9(5-6):457-67 - PubMed
    1. J Pharmacol Exp Ther. 1992 Feb;260(2):742-7 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources